Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
Sebastian Bauer, Robin L Jones, Jean-Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John R Zalcberg, Yoon-Koo Kang, Albiruni Abdul Razak, Jonathan Trent, Steven Attia, Axel Le Cesne, Ying Su, Julie Meade, Tao Wang, Matthew L Sherman, Rodrigo Ruiz-Soto, Michael C Heinrich, Sebastian Bauer, Robin L Jones, Jean-Yves Blay, Hans Gelderblom, Suzanne George, Patrick Schöffski, Margaret von Mehren, John R Zalcberg, Yoon-Koo Kang, Albiruni Abdul Razak, Jonathan Trent, Steven Attia, Axel Le Cesne, Ying Su, Julie Meade, Tao Wang, Matthew L Sherman, Rodrigo Ruiz-Soto, Michael C Heinrich
Abstract
Purpose: Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib is a switch-control TKI approved for advanced GIST after prior treatment with three or more TKIs, including imatinib. We compared efficacy and safety of ripretinib versus sunitinib in patients with advanced GIST who were previously treated with imatinib (INTRIGUE, ClinicalTrials.gov identifier: NCT03673501).
Patients and methods: Random assignment was 1:1 to once-daily ripretinib 150 mg or once-daily sunitinib 50 mg (4 weeks on/2 weeks off) and stratified by KIT/platelet-derived growth factor α mutation and imatinib intolerance. The primary end point was progression-free survival (PFS) by independent radiologic review using modified Response Evaluation Criteria in Solid Tumors version 1.1. Secondary end points included objective response rate by independent radiologic review, safety, and patient-reported outcome measures.
Results: Overall, 453 patients were randomly assigned to ripretinib (intention-to-treat [ITT], n = 226; KIT exon 11 ITT, n = 163) or sunitinib (ITT, n = 227; KIT exon 11 ITT, n = 164). Median PFS for ripretinib and sunitinib (KIT exon 11 ITT) was 8.3 and 7.0 months, respectively (hazard ratio, 0.88; 95% CI, 0.66 to 1.16; P = .36); median PFS (ITT) was 8.0 and 8.3 months, respectively (hazard ratio, 1.05; 95% CI, 0.82 to 1.33; nominal P = .72). Neither was statistically significant. Objective response rate was higher for ripretinib versus sunitinib in the KIT exon 11 ITT population (23.9% v 14.6%, nominal P = .03). Ripretinib was associated with a more favorable safety profile, fewer grade 3/4 treatment-emergent adverse events (41.3% v 65.6%, nominal P < .0001), and better scores on patient-reported outcome measures of tolerability.
Conclusion: Ripretinib was not superior to sunitinib in terms of PFS. However, meaningful clinical activity, fewer grade 3/4 treatment-emergent adverse events, and improved tolerability were observed with ripretinib.
Conflict of interest statement
Matthew L. Sherman
Employment: Deciphera, Pieris Pharmaceuticals
Leadership: Deciphera, Pieris Pharmaceuticals
Stock and Other Ownership Interests: Deciphera, Pieris Pharmaceuticals
No other potential conflicts of interest were reported.
Figures
References
- Rubin BP, Heinrich MC, Corless CL: Gastrointestinal stromal tumour. Lancet 369:1731-1741, 2007
- Søreide K, Sandvik OM, Søreide JA, et al. : Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol 40:39-46, 2016
- Hirota S, Isozaki K, Moriyama Y, et al. : Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580, 1998
- Heinrich MC, Corless CL, Duensing A, et al. : PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299:708-710, 2003
- Szucs Z, Thway K, Fisher C, et al. : Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol 13:93-107, 2017
- Vallilas C, Sarantis P, Kyriazoglou A, et al. : Gastrointestinal stromal tumors (GISTs): Novel therapeutic strategies with immunotherapy and small molecules. Int J Mol Sci 22:493, 2021
- Druker BJ, Talpaz M, Resta DJ, et al. : Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
- Blanke CD, Rankin C, Demetri GD, et al. : Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-632, 2008
- Novartis Pharmaceuticals Corporation : Gleevec (Imatinib Mesylate) Tablets, for Oral Use. Prescribing Information, 2020.
- National Comprehensive Cancer Network . NCCN Guidelines Gastrointestinal Stromal Tumors (GISTs) Version 1.2022, 2022.
- Hao Z, Sadek I: Sunitinib: The antiangiogenic effects and beyond. OncoTargets Ther 9:5495-5505, 2016
- Pfizer Labs . Sutent (Sunitinib Malate) Capsules, for Oral Use. Prescribing Information, 2021.
- Demetri GD, van Oosterom AT, Garrett CR, et al. : Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006
- Heinrich MC, Maki RG, Corless CL, et al. : Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26:5352-5359, 2008
- Nemunaitis J, Bauer S, Blay JY, et al. : Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. Future Oncol 16:4251-4264, 2020
- Smith BD, Kaufman MD, Lu WP, et al. : Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell 35:738-751.e9, 2019
- Blay JY, Serrano C, Heinrich MC, et al. : Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 21:923-934, 2020
- Deciphera Pharmaceuticals, LLC : QINLOCKTM (Ripretinib) Tablets: US Prescribing Information, 2021.
- Janku F, Abdul Razak AR, Chi P, et al. : Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: A phase I study of ripretinib. J Clin Oncol 38:3294-3303, 2020
- Hu C, Dignam JJ: Biomarker-driven oncology clinical trials: Key design elements, types, features, and practical considerations. JCO Precis Oncol
- Polley MC, Korn EL, Freidlin B: Phase III precision medicine clinical trial designs that integrate treatment and biomarker evaluation. JCO Precis Oncol
- Demetri GD, Reichardt P, Kang YK, et al. : Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:295-302, 2013
- Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI)—A simple practical measure for routine clinical use. Clin Exp Dermatol 19:210-216, 1994
- Fayers P Bottomley A; EORTC Quality of Life Group, et al. : Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer 38:S125-S133, 2002. (suppl 4)
- Dmitrienko A, Tamhane AC, Bretz F: Multiple Testing Problems in Pharmaceutical Statistics (ed 1). New York, NY, Chapman and Hall/CRC, 2009
- Li J, Gao J, Hong J, Shen L: Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors. Future Oncol 8:617-624, 2012
- Yoon DH, Ryu MH, Ryoo BY, et al. : Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: Relationship between efficacy and tumor genotype in Korean patients. Invest New Drugs 30:819-827, 2012
- Reichardt P, Demetri GD, Gelderblom H, et al. : Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. BMC Cancer 16:22, 2016
- Bauer S, Heinrich MC, George S, et al. : Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor harboring heterogeneous KIT/PDGFRA mutations in the phase III INVICTUS study. Clin Cancer Res 27:6333-6342, 2021
- Debiec-Rychter M, Sciot R, Le Cesne A, et al. : KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 42:1093-1103, 2006
- George S, Chi P, Heinrich MC, et al. : Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour. Eur J Cancer 155:236-244, 2021
- Zalcberg JR, Heinrich MC, George S, et al. : Clinical benefit of ripretinib dose escalation after disease progression in advanced gastrointestinal stromal tumor: An analysis of the INVICTUS study. Oncologist 26:e2053-e2060, 2021
- US Department of Health and Human Services, National Institutes of Health, National Cancer Institute : Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, 2017.
- Benedict C, DuHamel K, Nelson CJ: Reduction in social activities mediates the relationship between diarrhea and distress in rectal/anal cancer survivors. Psychooncology 27:691-694, 2018
- Lui M, Gallo-Hershberg D, DeAngelis C: Development and validation of a patient-reported questionnaire assessing systemic therapy induced diarrhea in oncology patients. Health Qual Life Outcomes 15:249, 2017
- Manfi Al-Rudayni AH, Gopinath D, Kannan Maharajan M, et al. : Impact of oral mucositis on quality of life in patients undergoing oncological treatment: A systematic review. Transl Cancer Res 9:3126-3134, 2020
- Fauske L, Hompland I, Lorem G, et al. : Perspectives on treatment side effects in patients with metastatic gastrointestinal stromal tumour: A qualitative study. Clin Sarcoma Res 9:6, 2019
- Sen F, Yildiz I, Basaran M, et al. : Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib. J BUON 18:775-781, 2013
- George S, Blay JY, Casali PG, et al. : Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 45:1959-1968, 2009
- Reichardt P, Kang YK, Rutkowski P, et al. : Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment-use trial of sunitinib. Cancer 121:1405-1413, 2015
Source: PubMed